LANCL1 and neoplasm: Currently, LANCL1-AS1 was shown to be downregulated in NSCLC cell lines and bioinformatics analysis revealed that its downregulation is associated with the adverse survival of LUAD patients, indicating the tumor suppressor role of LANCL1-AS1 in NSCLC.